Benjamin Besse, MD, PhD, Gustave Roussy Cancer Institute, Paris, discusses the results of the Phase I/II LIBRETTO-001 trial (NCT03157128), which assessed the safety and preliminary efficacy of selpercatinib in patients with RET fusion+ non-small cell lung cancer (NSCLC). 218 patients with prior platinum chemotherapy and 48 treatment-naïve patients were enrolled. Treatment with selpercatinib resulted in an improvement in objective response rate (ORR) and a well-tolerated safety profile. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.